This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The authors concluded that the nurse-led intervention was not clearly cost-effective. Although small benefits were observed, stricter targets in general practice and motivational measures were needed to achieve the best possible outcomes in south Asian patients with diabetes.
CRD commentary

Interventions:
The enhanced care system was described in the paper, with the authors presenting a reasonable description of the various components of the intervention (such as the nurse and link workers), but less detail of their tasks. Given the lack of detail surrounding their actual tasks the transferability of the intervention to other settings may be difficult.
Effectiveness/benefits:
The main objective was focused on the clinical analysis and as such the details of the clinical outcomes were well presented. However, due to this focus few details were presented on the derivation of the QALY and no data were presented on the baseline or final EQ-5D measurements.
Costs:
A study perspective was not reported. Further, given the lack of detail presented on the included costs and any adjustments made, it is difficult to ascertain if all appropriate costs have been considered or analysed appropriately. It is apparent that the main focus was the clinical trial, however, as the cost-effectiveness conclusions were presented, more details on the cost analysis would have allowed a better assessment on the validity of these conclusions.
Analysis and results:
The clinical trial would appear to have been well conducted. However, the economic evaluation was not well reported with only the mean incremental QALYs, the intervention costs and the incremental cost-effectiveness ratio being presented. No assessment of uncertainty was conducted and no ranges or confidence intervals were given. The level of reporting and the generalisability of the economic part of this study were rather limited.
Concluding remarks:
Although the methodology of the clinical study appears to have been appropriate and the reporting was clear and transparent, the economic evaluation was not reported in sufficient detail to allow any real assessment of its validity to be undertaken. Therefore, it is difficult to make an objective assessment of whether the authors' conclusions were robust.
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